These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 27503932)

  • 1. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
    Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS
    Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
    Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
    Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway.
    Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R
    Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis.
    Bi J; Zhang Q; Liang D; Xiong L; Wei H; Sun R; Tian Z
    Hepatology; 2014 May; 59(5):1715-25. PubMed ID: 24319005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells.
    Vendrame E; Seiler C; Ranganath T; Zhao NQ; Vergara R; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
    AIDS; 2020 May; 34(6):801-813. PubMed ID: 32028328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
    Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
    Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.
    Stiff A; Trikha P; Mundy-Bosse B; McMichael E; Mace TA; Benner B; Kendra K; Campbell A; Gautam S; Abood D; Landi I; Hsu V; Duggan M; Wesolowski R; Old M; Howard JH; Yu L; Stasik N; Olencki T; Muthusamy N; Tridandapani S; Byrd JC; Caligiuri M; Carson WE
    Clin Cancer Res; 2018 Apr; 24(8):1891-1904. PubMed ID: 29363526
    [No Abstract]   [Full Text] [Related]  

  • 9. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of inhibitory receptor TIGIT to NK cell education.
    He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
    J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.
    Seel K; Schirrmann RL; Stowitschek D; Ioseliani T; Roiter L; Knierim A; André MC
    Cancer Immunol Immunother; 2024 Jul; 73(9):180. PubMed ID: 38967649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk.
    Bi J; Zheng X; Chen Y; Wei H; Sun R; Tian Z
    Hepatology; 2014 Oct; 60(4):1389-98. PubMed ID: 24912841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
    Wang Z; Weiner GJ
    J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
    Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N
    Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-like Monocytes Increase in Patients with Colon Cancer and Induce Dysfunctional TIGIT+ NK Cells.
    Calabrò A; Drommi F; Sidoti Migliore G; Pezzino G; Vento G; Freni J; Costa G; Cavaliere R; Bonaccorsi I; Sionne M; Nigro S; Navarra G; Ferlazzo G; De Pasquale C; Campana S
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals.
    Yin X; Liu T; Wang Z; Ma M; Lei J; Zhang Z; Fu S; Fu Y; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
    Front Immunol; 2018; 9():2341. PubMed ID: 30364127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cell-based therapeutics for lung cancer.
    Pockley AG; Vaupel P; Multhoff G
    Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
    [No Abstract]   [Full Text] [Related]  

  • 20. Limited Impact of the Inhibitory Receptor TIGIT on NK and T Cell Responses during
    Aldridge DL; Phan AT; de Waal Malefyt R; Hunter CA
    Immunohorizons; 2021 Jun; 5(6):384-394. PubMed ID: 34088852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.